234 related articles for article (PubMed ID: 2491940)
21. Fluvoxamine as an antiobsessional agent.
Goodman WK; Price LH; Rasmussen SA; Heninger GR; Charney DS
Psychopharmacol Bull; 1989; 25(1):31-5. PubMed ID: 2505302
[TBL] [Abstract][Full Text] [Related]
22. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
[TBL] [Abstract][Full Text] [Related]
23. Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study.
Zohar J; Kaplan Z; Benjamin J
J Clin Psychiatry; 1994 Mar; 55(3):86-8. PubMed ID: 8071253
[TBL] [Abstract][Full Text] [Related]
24. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
25. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder.
Delgado PL; Goodman WK; Price LH; Heninger GR; Charney DS
Br J Psychiatry; 1990 Nov; 157():762-5. PubMed ID: 2126219
[TBL] [Abstract][Full Text] [Related]
26. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report.
McDougle CJ; Price LH; Goodman WK
J Autism Dev Disord; 1990 Dec; 20(4):537-43. PubMed ID: 2126264
[TBL] [Abstract][Full Text] [Related]
27. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
[TBL] [Abstract][Full Text] [Related]
28. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
[TBL] [Abstract][Full Text] [Related]
29. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
Goodman WK; Kozak MJ; Liebowitz M; White KL
Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
[TBL] [Abstract][Full Text] [Related]
30. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
[TBL] [Abstract][Full Text] [Related]
31. The Yale-Brown Obsessive Compulsive Scale. II. Validity.
Goodman WK; Price LH; Rasmussen SA; Mazure C; Delgado P; Heninger GR; Charney DS
Arch Gen Psychiatry; 1989 Nov; 46(11):1012-6. PubMed ID: 2510699
[TBL] [Abstract][Full Text] [Related]
32. [Obsessive-compulsive symptoms associated with panic disorder. Predictive factor of a good therapeutic response to fluvoxamine].
Servant D; Bailly D; Le Seac'h H; Parquet PJ
Encephale; 1990; 16 Spec No():359-62. PubMed ID: 2120029
[TBL] [Abstract][Full Text] [Related]
33. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
Paydary K; Akamaloo A; Ahmadipour A; Pishgar F; Emamzadehfard S; Akhondzadeh S
J Clin Pharm Ther; 2016 Apr; 41(2):214-9. PubMed ID: 26931055
[TBL] [Abstract][Full Text] [Related]
34. Treatment of major affective disorder with fluvoxamine.
Lapierre YD; Browne M; Horn E; Oyewumi LK; Sarantidis D; Roberts N; Badoe K; Tessier P
J Clin Psychiatry; 1987 Feb; 48(2):65-8. PubMed ID: 3100510
[TBL] [Abstract][Full Text] [Related]
35. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder.
Cottraux J; Mollard E; Bouvard M; Marks I; Sluys M; Nury AM; Douge R; Cialdella P
Int Clin Psychopharmacol; 1990 Jan; 5(1):17-30. PubMed ID: 2110206
[TBL] [Abstract][Full Text] [Related]
36. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
37. Comparing the Effects of a Herbal Drug based on
Noras MR; Soltanifar A; Salari R; Jarahi L; Abrishami MH
Curr Drug Discov Technol; 2022; 19(5):e240622206368. PubMed ID: 35748547
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
[TBL] [Abstract][Full Text] [Related]
40. Successful fluvoxamine treatment of a case of refractory obsessive-compulsive disorder.
Solyom L; Solyom CA
Can J Psychiatry; 1990 Nov; 35(8):696-8. PubMed ID: 2126485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
